Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC)

Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: 69ee056663a4153ffbd62ced87422350d87d0cf6
First added on: Feb 12, 2025